Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Gilead_Sciences
|
| gptkbp:acquisitionYear |
2020
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
oncology
antibody-drug conjugates |
| gptkbp:foundedIn |
1982
|
| gptkbp:founder |
gptkb:David_M._Goldenberg
|
| gptkbp:headquartersLocation |
gptkb:Morris_Plains,_New_Jersey,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Immunomedics, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notablePerson |
Behzad Aghazadeh
|
| gptkbp:notableProduct |
gptkb:Trodelvy
|
| gptkbp:product |
gptkb:sacituzumab_govitecan
IMMU-132 IMMU-140 |
| gptkbp:status |
defunct
|
| gptkbp:stockSymbol |
gptkb:IMMU
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:bfsParent |
gptkb:David_M._Goldenberg
gptkb:IMMU |
| gptkbp:bfsLayer |
7
|